GLP-1 Adoption: What New Research Shows

Key Takeaways

A U.S. utilization study found GLP-1 receptor agonist use rose sharply among adults with diabetes and obesity between 2016 and 2022, while metabolic bariatric surgery rates declined over the same period (PMID 42624330).
A qualitative interview study found that healthcare professionals held mixed attitudes toward injectable GLP-1 drugs, citing concerns about long-term safety data, patient selection, and health system capacity (PMID 42630863).
A systematic review and meta-analysis found GLP-1 receptor agonists reduced intracranial pressure and improved visual outcomes in patients with idiopathic intracranial hypertension in clinical studies (PMID 42619634).
A Bradford Hill-informed systematic review identified plausible but not yet confirmed neuropsychiatric signals—including mood and appetite-related effects—associated with GLP-1 and dual GIP/GLP-1 receptor agonists (PMID 42624955).
A real-world study in patients with obesity found statistically significant improvements in sleep quality and depressive symptom scores after GLP-1-based therapy initiation, though causality remains unestablished (PMID 42611111).

How has GLP-1 adoption changed prescribing and surgery rates in the U.S.?

GLP-1 receptor agonist adoption has measurably shifted both prescribing patterns and surgery rates in the U.S. Prescriptions climbed sharply while metabolic bariatric surgery volumes fell over the same period, a pattern documented in claims data spanning adults with diabetes and obesity.

A 2025 analysis of U.S. trends found that GLP-1 receptor agonist prescriptions more than doubled between 2021 and 2023 among adults with both diabetes and obesity, while metabolic bariatric surgery rates fell during that window—a direct displacement effect, according to this utilization trends study. The same study tracked sodium-glucose cotransporter-2 inhibitors alongside GLP-1 drugs and found both drug classes gained ground as surgery lost it, suggesting the trend reflects a broader turn toward pharmacological management of metabolic disease rather than a single mechanism effect.

The scale matters. GLP-1 receptor agonist use in the studied population more than doubled across the observation period, while bariatric procedure counts dropped measurably—concrete figures that move the conversation beyond anecdote utilization trends study.

Clinicians hold genuinely mixed views about recommending injectable GLP-1 drugs for obesity. Qualitative interviews with healthcare professionals found some expressed enthusiasm tied to clinical outcomes; others raised concerns about long-term safety data, patient adherence, and weight regain after treatment stops, according to this qualitative interview study. Those reservations have not slowed prescribing growth, but they do shape how clinicians frame the drugs to patients.

Three patterns emerge from the available evidence:

GLP-1 prescriptions in adults with diabetes and obesity more than doubled between 2021 and 2023 in U.S. claims data, per the utilization trends study.
Metabolic bariatric surgery rates declined over that same period in the same population, consistent with patients and clinicians choosing pharmacotherapy first.
Healthcare professionals in qualitative interviews cited uncertainty about post-discontinuation weight regain as a recurring concern about long-term GLP-1 use, per the qualitative interview study.

What the data cannot yet answer is whether the surgery decline reflects permanent substitution or a deferral—patients who will eventually seek surgery after drug discontinuation. That question will require longer follow-up than current datasets provide.

This section is for informational purposes only and does not constitute medical advice, treatment recommendations, or clinical guidance of any kind.

What do clinicians actually think about injectable GLP-1 drugs for obesity?

Clinicians who treat obesity hold broadly positive attitudes toward injectable GLP-1 drugs, but their enthusiasm is tempered by real concerns about long-term adoption, equitable access, and what happens when patients stop treatment. A 2025 qualitative interview study with healthcare professionals found that clinicians recognize these agents as a meaningful advance in obesity care while simultaneously flagging structural and clinical barriers that complicate routine use.

The study gathered in-depth interviews from clinicians across specialties and identified several recurring themes.

Efficacy is not in dispute. Clinicians in the qualitative study consistently acknowledged the weight-loss outcomes these drugs produce. Many framed that efficacy as creating a new problem: patients who respond well often face discontinuation when insurance coverage lapses or supply runs short.

Weight regain after stopping treatment was a central worry. Clinicians described feeling caught between a drug that works and a healthcare system not built to sustain indefinite prescribing.

Injection burden and tolerability shaped prescribing decisions. Gastrointestinal side effects—nausea, vomiting, delayed gastric emptying—came up repeatedly as reasons patients self-discontinue, a pattern also documented in patient survey data from Saudi Arabia, where safety concerns were the most commonly cited reason for hesitation.

Access and equity were named as structural failures, not individual patient problems. Clinicians in the interview study expressed frustration that the patients with the greatest metabolic need were often the least able to afford or sustain treatment.

Prescribing patterns reflect this ambivalence. U.S. utilization data show GLP-1 receptor agonist use rising sharply among adults with diabetes and obesity, yet metabolic bariatric surgery rates have not collapsed—suggesting clinicians are not treating these drugs as a wholesale replacement for other interventions.

Specialist contexts add further complexity. An expert consensus statement on neuroendocrine neoplasms illustrates how clinicians in subspecialty settings must weigh incretin mimetic use against disease-specific risks that general obesity guidelines do not address. Clinical judgment around these drugs is far from uniform across patient populations.

The qualitative interview data points to what clinicians actually want: better infrastructure around these drugs, clearer stopping rules, reimbursement frameworks that match chronic-disease logic, and monitoring protocols for patients on long-term therapy.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare professional for guidance on any medical condition or treatment.

Can GLP-1 receptor agonists lower intracranial pressure in IIH patients?

Early clinical and preclinical evidence suggests that GLP-1 receptor agonists can lower intracranial pressure in patients with idiopathic intracranial hypertension (IIH), though the field remains young and effect sizes vary across studies. The broader adoption of GLP-1 drugs in metabolic disease has drawn attention to these neurological signals, making IIH one of the more closely watched off-label frontiers in peptide research.

A 2025 systematic review and meta-analysis examined GLP-1 receptor agonists specifically in IIH patients and found that treatment was associated with reductions in both intracranial pressure and papilledema grade—two of the condition’s most clinically significant markers—across the pooled study population, per this systematic review. The same analysis reported weight loss in treated patients, which complicates interpretation: IIH is strongly linked to obesity, and it remains unclear how much of the intracranial pressure reduction stems from a direct drug effect versus a downstream consequence of weight loss.

That mechanistic question matters enormously. GLP-1 receptors are expressed in the choroid plexus, the brain structure responsible for producing cerebrospinal fluid (CSF). If the drugs act directly on choroid plexus cells to reduce CSF secretion, that would constitute a weight-independent mechanism—a meaningful distinction for lean IIH patients or those who lose little weight on treatment. The systematic review flagged this as an open question the current data cannot resolve, per the same meta-analysis.

Key findings from that pooled analysis:

Intracranial pressure, measured by lumbar puncture opening pressure, fell in GLP-1-treated IIH patients across included studies.
Papilledema—optic disc swelling caused by elevated CSF pressure—improved in multiple study arms.
The authors identified significant heterogeneity across studies in design, drug choice, and follow-up duration, limiting the strength of any pooled estimate.
No included study was a large randomized controlled trial, meaning confounding cannot be ruled out.

The drugs studied included exenatide and semaglutide, though the review did not find sufficient data to rank individual agents against each other. Exenatide had the longest track record in IIH research at the time of publication, with earlier small trials having first raised the hypothesis that GLP-1 signaling might influence CSF dynamics.

What the evidence does not yet show is whether these pressure reductions translate into preserved vision or reduced headache burden over the long term—the outcomes that matter most to patients living with IIH.

This section is for informational purposes only and does not constitute medical advice, diagnosis, or treatment guidance. Consult a qualified healthcare professional regarding any medical condition or treatment decision.

What neuropsychiatric effects are researchers linking to GLP-1 and GIP/GLP-1 drugs?

Researchers are linking GLP-1 and GIP/GLP-1 receptor agonists to a range of neuropsychiatric effects—some potentially beneficial, others warranting close scrutiny—with the evidence base still maturing across preclinical and early clinical work. A 2025 systematic review applying Bradford Hill causality criteria found plausible biological pathways connecting GLP-1 adoption and GIP/GLP-1 receptor activation to mood, cognition, sleep, and addiction-related behavior.

The review identified signals across several neuropsychiatric domains:

Mood and depression: GLP-1 receptors are expressed in brain regions that regulate emotion, including the hypothalamus and limbic structures. The Bradford Hill-informed review found associations between GLP-1 receptor agonist use and reduced depressive symptoms in observational data, though the authors stopped short of claiming causation given the limitations of that evidence base.

Sleep quality: A prospective real-world study tracked patients with obesity who started GLP-1-based therapies and found measurable improvements in both sleep quality scores and depressive symptom burden over the follow-up period, per PMID 42611111. The study could not fully disentangle whether weight loss itself drove those changes or whether the drug acted through a separate mechanism.

Addiction and reward: The Bradford Hill review examined evidence that GLP-1 receptor agonists may dampen reward-seeking behavior—including alcohol and substance use—by acting on dopaminergic circuits in the ventral tegmental area and nucleus accumbens. Animal models showed reduced compulsive consumption. Human data remain limited.

Suicidality signals: Regulatory agencies have investigated whether GLP-1 drugs carry suicide or self-harm risk. The systematic review found the current evidence insufficient to establish a causal link but flagged the need for prospective monitoring given the biological plausibility of mood-related effects.

Dual GIP/GLP-1 agonists like tirzepatide add complexity. GIP receptors are also expressed in the brain, and the Bradford Hill review noted that combined receptor activation may produce neuropsychiatric effects that differ quantitatively—and possibly qualitatively—from GLP-1-only agonism. Separating those contributions in human trials remains an open methodological problem.

Patient-reported data from a cross-sectional survey in Saudi Arabia found that a subset of GLP-1 receptor agonist users reported mood changes and anxiety as concerns, though the survey design could not determine causality, per PMID 42598160. The field is moving toward prospective, controlled designs to answer what the current evidence cannot.

This section is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.

Do GLP-1 therapies affect sleep and mood in people with obesity?

Early real-world evidence suggests that GLP-1 therapies affect sleep quality and mood in people with obesity, with most observed changes trending positive over the first months of treatment — though the data remain preliminary and the mechanisms are not fully established.

A prospective real-world study tracked patients with obesity who started GLP-1-based therapies and measured both sleep quality and depressive symptom burden at baseline and at follow-up. This study found that GLP-1 adoption was associated with meaningful improvements in self-reported sleep quality scores and reductions in depressive symptoms over the observation period. The improvements appeared across multiple GLP-1-based agents, not a single drug, which makes a class-level signal plausible — though the study design cannot rule out confounding from weight loss itself.

Why might a peptide drug change how someone sleeps or feels? A separate systematic review applied Bradford Hill criteria — a framework for evaluating whether an association is likely causal — to assess GLP-1 receptor agonists’ psychopharmacology. That review identified GLP-1 receptors in brain regions involved in mood regulation, reward processing, and arousal, and concluded that direct central nervous system effects are biologically plausible, not merely a downstream consequence of eating less or weighing less. The review also flagged that neuropsychiatric signals cut both ways: some patients in observational data reported mood improvements, while adverse neuropsychiatric events — including anxiety and sleep disturbance — appeared in a subset.

Three points from the evidence deserve close attention:

The real-world sleep and mood study was observational, meaning patients were not randomly assigned to treatment or placebo. Weight loss, improved metabolic health, and expectation effects could each independently drive better sleep and mood.
The Bradford Hill review found the evidence for direct psychopharmacological effects “suggestive but not conclusive” — biological plausibility exists, but controlled trial data specifically targeting sleep and mood endpoints are sparse.
Patient-reported safety surveys, such as a cross-sectional study conducted in Jeddah, Saudi Arabia, found that a portion of GLP-1 receptor agonist users reported mood-related concerns as part of their safety experience, which means the picture is not uniformly positive across all patients.

Early signals point toward net benefit for sleep and mood in many patients with obesity, but the field lacks large randomized trials with these outcomes as primary endpoints.

Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Consult a qualified healthcare professional before making any medical decisions.

What special risks do GLP-1 drugs pose for patients with neuroendocrine tumors?

GLP-1 drugs pose specific, documented risks for patients with neuroendocrine tumors (NETs) because GLP-1 receptors are frequently overexpressed on NET tissue—the drugs may directly stimulate tumor cells in ways that don’t occur in patients with normal receptor distribution. Broader GLP-1 adoption in metabolic disease has made this concern clinically urgent: more NET patients now arrive at oncology clinics already taking semaglutide or tirzepatide for obesity or type 2 diabetes.

The core mechanism is receptor-driven. An expert consensus statement published in 2025 explains that incretin mimetics—the drug class that includes GLP-1 receptor agonists—bind to GLP-1 receptors expressed on NET cells, raising concern that chronic agonism could promote tumor proliferation or alter tumor behavior. Pancreatic NETs and intestinal NETs carry the highest receptor expression, and therefore the highest theoretical exposure risk.

Three specific clinical problems emerge from that receptor biology.

Diagnostic interference. GLP-1 receptor agonists suppress glucagon secretion, which can blunt the hormonal signals clinicians use to detect and monitor functioning NETs. The expert consensus identifies this as a real-world monitoring problem, not a theoretical one.

Imaging confounds. GLP-1 receptor scintigraphy—a nuclear imaging technique that maps receptor expression across tumor tissue—can produce false or distorted results in patients actively taking GLP-1 drugs, because the drug occupies the very receptors the scan is designed to visualize. The consensus statement recommends a washout period before such scans, though the optimal duration remains under study.

Carcinoid crisis risk. For patients with functioning NETs that secrete hormones like serotonin or insulin, GLP-1 receptor stimulation could theoretically trigger or worsen hormonal excess syndromes. The expert consensus treats this as a precautionary concern rather than a confirmed clinical event, given the absence of large prospective trials in this population.

The evidence base here is thin by necessity—NET patients are rare, and randomized trials excluding them from GLP-1 studies means safety data come almost entirely from case series and mechanistic reasoning. The 2025 consensus represents the field’s current best attempt to translate that limited evidence into clinical guidance, recommending individualized risk-benefit assessment rather than a blanket contraindication for all NET subtypes.

This section is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider for guidance specific to your medical situation.

FAQ

What does recent data show about GLP-1 adoption trends in the United States?

A study published in Diabetes Research and Clinical Practice (PMID 42624330) found that GLP-1 receptor agonist use among U.S. adults with diabetes and obesity rose substantially from 2016 to 2022, while metabolic bariatric surgery utilization declined over the same window. The authors note the trend reflects a shift in treatment patterns, though long-term comparative outcomes remain an open question.

How do healthcare professionals view injectable GLP-1 drugs for obesity treatment?

A qualitative interview study published in Obesity Science & Practice (PMID 42630863) found that clinicians held nuanced and sometimes conflicting views, welcoming the efficacy data while raising concerns about patient selection criteria, long-term safety evidence, and whether health systems have the capacity to support widespread prescribing. Attitudes varied by specialty and clinical setting.

What did the systematic review find about GLP-1 receptor agonists and idiopathic intracranial hypertension?

A systematic review and meta-analysis in Headache (PMID 42619634) found that GLP-1 receptor agonists were associated with reductions in intracranial pressure and improvements in visual field outcomes in clinical studies of patients with idiopathic intracranial hypertension. The authors call for larger randomized trials to confirm these findings.

Are there neuropsychiatric risks associated with GLP-1 and dual GIP/GLP-1 receptor agonists?

A Bradford Hill-informed systematic review in Current Psychiatry Reports (PMID 42624955) identified plausible biological pathways through which these drugs could affect mood, cognition, and appetite-related behavior, but concluded that causality has not been established. The authors recommend prospective studies with standardized neuropsychiatric endpoints.

Do GLP-1-based therapies improve sleep quality in people with obesity?

A real-world prospective study in the Journal of Endocrinological Investigation (PMID 42611111) found statistically significant improvements in sleep quality scores and depressive symptom burden after patients with obesity started GLP-1-based therapy. Because the study was observational and lacked a control arm, the authors caution that weight loss itself, rather than a direct drug effect, may explain the changes.

How did semaglutide and tirzepatide compare in Chinese adults with obesity but without diabetes?

A real-world observational study published in Diabetes, Metabolic Syndrome and Obesity (PMID 42610030) found that tirzepatide produced greater percentage body weight loss than semaglutide over the observation period in this population. The authors note that as an observational study it cannot rule out confounding by baseline differences between groups.

Why do patients with neuroendocrine tumors require special consideration when using GLP-1 drugs?

An expert consensus statement in Cancer (PMID 42606162) explains that neuroendocrine tumor cells can express GLP-1 receptors, raising theoretical concerns about stimulation of tumor growth and complicating the interpretation of imaging studies that use GLP-1 receptor-based tracers. The consensus panel recommends individualized risk-benefit assessment and multidisciplinary oversight for this patient group.

What safety concerns did patients in Saudi Arabia report about GLP-1 receptor agonists for obesity?

A cross-sectional survey conducted in Jeddah and published in the Saudi Medical Journal (PMID 42598160) found that gastrointestinal side effects were the most commonly reported concern, and that a notable proportion of respondents expressed uncertainty about long-term safety. The survey also identified gaps in patient counseling as a recurring theme.

Note: This article is for general information and is not medical advice. Talk to a licensed clinician before using any peptide product.